FIS Announces Date Change For Fourth Quarter Earnings to February 13, 2023

FIS ® (NYSE: FIS), a global leader in financial services technology, today announced that it has changed its earnings release date for fourth quarter 2022 financial results to Mon., Feb. 13, 2023, prior to market open.

The company will sponsor a live webcast of its earnings conference call with the investment community beginning at 8:30 a.m. (EST) the same day. To access the webcast, go to the Investor Relations section of FIS' homepage, www.fisglobal.com . A replay will be available after the conclusion of the live webcast.

About FIS

FIS is a leading provider of technology solutions for financial institutions and businesses of all sizes and across any industry globally. We enable the movement of commerce by unlocking the financial technology that powers the world's economy. Our employees are dedicated to advancing the way the world pays, banks and invests through our trusted innovation, system performance and flexible architecture. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS is a member of the Fortune 500 ® and the Standard & Poor's 500 ® Index. To learn more, visit www.fisglobal.com . Follow FIS on Facebook , LinkedIn and Twitter ( @FISGlobal ).

Kim Snider
Senior Vice President
FIS Global Marketing and Corporate Communications
904.438.6278
kim.snider@fisglobal.com

George Mihalos
Senior Vice President
Head of Investor Relations
904.438.6119
georgios.mihalos@fisglobal.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
Walker Lane Resources Ltd. Announces Closing of Private Placement

Walker Lane Resources Ltd. Announces Closing of Private Placement

Walker Lane Resources Ltd. (TSX - V: WLR) (F r ankfurt:6YL ) ("WLR" o r t h e " Comp a ny") is pleased to announce, further to its news releases of June 10, 2025, that it has received TSX Venture Exchange approval to close the non-brokered private placement (the " Private Placement "). On July 23, 2025, the Company issued 2,508,335 non-flow through Units (each a " NFT Unit ") at a price of $0.12 per NFT Unit, for gross proceeds of $301,000, and 607,143 flow-through Units (each a " FT Unit ") at a price of $0.14 per FT Unit, for gross proceeds of $85,000, for aggregate gross proceeds of $386,000. Each NFT Unit is composed of one common share and one common share purchase warrant (each whole warrant, a " NFT Warrant "). Each FT Unit is composed of one common share and one common share purchase warrant (each whole warrant, a " FT Warrant "), each NFT Warrant and each FT Warrant are exercisable for two (2) years at $0.16 per common share.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

GLOBEX MINING ENTERPRISES INC. (GMX Toronto Stock Exchange, G1MN Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exch anges and GLBXF OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (BRW-TSXV, BRWXF-OTCQB) in a press release today, announced additional wide intersections of lithium mineralization on Globex's Lac Escale royalty claims, a part of Brunswick's Mirage property.

Intersections include 36 meters grading 1.51% Li 2 O in Hole MR-24-102 and 1.32% Li 2 O over 28 metres in Hole MR-24-101. A total of 24 drill holes were completed in the winter drill program. Please access Brunswick's press release of today's date for further details.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Latest Press Releases

Related News

×